Literature DB >> 7924696

Flow cytometric method for the measurement of epidermal growth factor receptor and comparison with the radio-ligand binding assay.

I Brotherick1, T W Lennard, S E Wilkinson, S Cook, B Angus, B K Shenton.   

Abstract

A method for the purification, conjugation, and use of EGF-R antibody to quantify EGF receptors on tumour cells by flow cytometry is described. The quantification of both internal and external EGF receptors was determined by treatment with saponin, rendering the cells permeable to the EGF-R antibody. Using QCS bead standards, the number of EGF-R binding sites per cell was assessed. Results were compared with conventional EGF-R quantification using a radio-ligand binding assay. A high degree of correlation was found between the two methods. The flow cytometric method for EGF-R quantification described is simple, rapid, and reproducible. The assay may be of particular value in measuring EGF-R on urgent clinical samples or those that are too small (such as breast aspirates) for measurement by the radio-ligand binding assay. Advantages of this assay over the radio-ligand binding assay include reduction in use of radio-labelled iodine compounds, a decrease in analysis time, and reduced cost and quantity of material needed for assay. In addition, flow cytometry offers the possibility of selecting cell phenotypes by gating as well as live/dead cells by using multi-parameter flow cytometry.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7924696     DOI: 10.1002/cyto.990160311

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  10 in total

1.  Quantitation of estrogen receptors and relaxin binding in human anterior cruciate ligament fibroblasts.

Authors:  Deborah A Faryniarz; Madhu Bhargava; Claudette Lajam; Erik T Attia; Jo A Hannafin
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Jul-Aug       Impact factor: 2.416

2.  The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer.

Authors:  I Brotherick; B K Shenton; W K Cowan; B Angus; C H Horne; M J Higgs; T W Lennard
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

3.  p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer.

Authors:  I Brotherick; B K Shenton; W K Cowan; B Angus; C H Horne; M J Higgs; T W Lennard
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

4.  A flow cytometric study of c-erbB-3 expression in breast cancer.

Authors:  I Brotherick; B K Shenton; B Angus; I S Waite; C H Horne; T W Lennard
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

5.  Expression of oestrogen and progesterone receptors in gastric cancer: a flow cytometric study.

Authors:  D Karat; I Brotherick; B K Shenton; D Scott; S A Raimes; S M Griffin
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

6.  A Miniaturized Ligand Binding Assay for EGFR.

Authors:  Jochen M Schwenk; Oliver Poetz; Robert Zeillinger; Thomas O Joos
Journal:  Int J Proteomics       Date:  2012-04-08

7.  The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study.

Authors:  I Brotherick; D A Browell; B K Shenton; M Egan; W J Cunliffe; L A Webb; L G Lunt; J R Young; M J Higgs
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

8.  Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours.

Authors:  J E Nutt; J K Mellon; K Qureshi; J Lunec
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

9.  Are fine-needle breast aspirates representative of the underlying solid tumour? A comparison of receptor levels, ploidy and the influence of cytokeratin gates.

Authors:  I Brotherick; B K Shenton; T W Lennard
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

10.  Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.

Authors:  J E Nutt; H P Lazarowicz; J K Mellon; J Lunec
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.